Скачать или смотреть Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer

Dr Sara Tolaney speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the ATEMPT randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel in combination with trastuzumab (TH) for stage I HER2-positive breast cancer.

The study follows on from the APT trial, which demonstrated favourable outcomes from treating HER2-positive breast cancer patients with adjuvant paclitaxel and trastuzumab. Dr Tolaney explains that the hoped to find a less toxic treatment option for this patient population.

She reports that the study met the disease-free survival endpoint and, while the clinically-relevant toxicity was the same in both arms, the toxicity profiles did differ.

Dr Tolaney says that the next step is to try a shorter duration of T-DM1 before continuing with trastuzumab, and also discusses the financial toxicity of the treatment.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php